UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buys

September 28, 2024

Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:

More To Explore

Shares slip in Asia, dollar firm as inflation, earnings loom

The impact of the jobs report on U.S. rate cut prospects also raised the stakes for consumer price figures on Wednesday where any rise in

January 13, 2025

Three companies line up $1-billion bond issues overseas

Tata Group’s non-banking arm Tata Capital ($300 million), Prem Watsa-backed IIFL Finance ($300 million) and Anil Agarwal’s Vedanta Resources ($500 million) are ready to hit

January 13, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003